Compare BioNTech SE - ADR (BNTX) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Wheaton Precious Metals Corp — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Wheaton Precious Metals Corp trades at $134.14 (market cap $60.94B). The key difference: Wheaton Precious Metals Corp is far larger — about 2.6× BioNTech SE - ADR's market cap, and Wheaton Precious Metals Corp pays a 0.58% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | WPM | |
|---|---|---|
Market Cap | $23.31B | $60.94B |
Sector | Health | Basic Materials |
52-Week High | $119.34 | $165.72 |
52-Week Low | $83.89 | $91.02 |
Enterprise Value | $6.60B | $62.82B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
Wheaton Precious Metals (WPM) trades at $135.00, up 1.21% on the day, with a bullish technical signal supported by moving averages. The company reported record first-half 2026 results, with Q2 earnings of $1.19 per share beating estimates, driven by higher metal prices and sales volumes. Strong profitability is evident with a net income margin of 64.66% and robust cash flow from operations of $1.90 billion in 2025. Analyst consensus is strongly positive with a buy rating from 80% of covering firms and a price target of $161.75.
The outlook remains favorable given sustained high precious metal prices and operational execution, though elevated valuation multiples and potential commodity price volatility present risks. Upside is supported by consistent earnings beats and institutional confidence, but investors should weigh the stock's premium pricing against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
